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Heparin-bonded Dacron or polytetrafluorethylene
for femoropopliteal bypass: Five-year results of a
prospective randomized multicenter clinical trial
Carol Devine, BA, and Charles McCollum, MD, FRCS, on behalf of The North West Femoro-Popliteal
Trial Participants, Manchester, England
Objective: Dacron was largely abandoned for femoropopliteal bypass 30 years ago, because better patency rates were
achieved with saphenous vein. Despite the range of potential prosthetics, polytetrafluoroethylne (PTFE) clearly
predominates in current femoropopliteal practice. We compared heparin-bonded Dacron (HBD) with PTFE in a
randomized multicenter clinical trial.
Method:Over 28 months, 209 patients (179 above-knee disease, 30 below-knee disease) were randomized to receive HBD
(n  106) or PTFE (n  103) grafts. Aspirin, 300 mg/d, was started before surgery, and was continued if tolerated.
Results: At follow-up for a minimum of 5 years (mean, 76 months; range, 60-89 months), 37 patients (17.7%) had died
with patent grafts and 121 (58%) grafts were occluded. Primary patency rate, measured with Kaplan-Meier survival
analysis, was 46% (95% confidence interval [CI], 35%-57%) at year 5 for HBD, compared with 35% for PTFE (CI,
25%-45%; P < .055). Long-term patency was achieved in only 4 of 78 interventions performed in 55 thrombosed grafts.
Secondary patency rate for HBDwas 47% (CI, 36%-58%), and for PTFE was 36% (CI, 26%-46%). Risk factors for arterial
disease did not significantly influence prosthetic patency. Major limb amputation was necessary in 9 patients with HBD
grafts and 20 patients with PTFE grafts (P< .025). Two amputations in the HBD group and 8 amputations in the PTFE
group were in patients undergoing bypass surgery to treat claudication only. Limb salvage rate was 86% (CI, 77%-95%)
and 74% (CI, 64%-84%), respectively.
Conclusions: Significantly better patency rates were achieved with HBD than with PTFE at 3 years (P < .044), but the
difference was no longer statistically significant at 5 years (P< .055). The incidence of major limb amputation, however,
was significantly greater (P< .025) in the PTFE group compared with theHBD group at both 3 and 5 years of follow-up.
(J Vasc Surg 2004;40:924-31.)Controversy still exists regarding material and tech-
niques for use in femorodistal bypass in peripheral arterial
occlusive disease. There is no clear evidence on the optimal
graft for femoropopliteal grafting.1Clearly, better results
are achieved with saphenous vein in below-knee (BK) by-
pass procedures, but in those procedures where the distal
anastomosis is above the knee (AK) the question as to
whether prosthetic materials such as polytetrafluroethylene
(PTFE), Dacron, and human umbilical vein are equivalent
to saphenous vein is still debated.2-9 Today we accept that
new products should be evaluated in randomized controlled
trials before introduction to clinical practice. This was not
always so. Vascular grafts previously had been introduced by
individual surgeons, who reported excellent results, often by
virtue of unusual technical ability or careful case selection.10-12
In March 2001 this Journal published our interim
report on a randomized multicenter trial comparing colla-
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924gen-coated, heparin-bonded Dacron (HBD) prostheses
with PTFE grafts in all patients undergoing elective AK
reconstructions and those undergoing BK reconstructions
for which saphenous vein was not available.13 Full details of
patients, methods, preoperative assessments, randomiza-
tion, follow-up, sample size, trial end points, and statistical
analysis are given in that interim paper,13 and are summa-
rized here. The interim analysis was performed when pa-
tients had completed follow-up to more than 2 years
(mean, 42 months; range, 28-55 months). Life table anal-
ysis demonstrated that better patency rate was achieved
with HBD (55%) than with PTFE (42%; P .044). Seven-
teen patients with PTFE grafts underwent amputation,
compared with only 6 patients withHBDgrafts (P .015).
We now report the results when all patients have completed
follow-up for a minimum of 5 years (mean, 76 months;
range, 60-89 months).
Dacron grafts were, for the most part, abandoned for
femoropopliteal bypass, because early experience proved
disappointing. At the time, neither the role of platelets in
generating thrombus on the luminal surface of prosthetic
grafts nor the value of platelet inhibitory drug therapy was
appreciated. This left the choice between PTFE and human
umbilical vein. In randomized trials better patency rates
tended to be achieved with human umbilical vein compared
with PTFE,5,14-16 but clinical practice changed little, pre-
sumably because surgeons were unconvinced that this small
le-brac
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cal demands of human umbilical vein use.
Perhaps the most important observation in the Medical
Research Council–funded randomized femoropopliteal
trial conducted in the United Kingdom, which compared
human umbilical vein grafts with PTFE grafts, was that in a
total of 801 femoropopliteal grafts recruited to the study by
48 vascular surgeons there was no essential difference in the
Table I. Risk factors
HB
(N 
Age (y)
Mean 65.9
Range 33–8
Gender (%)
Male 69.8
Female 30.2
Angina/myocardial infarction (%) 33
Cardiac failure (%) 9.4
Carotid disease, symptomatic (%) 18.9
Diabetes (%) 14.2
Hypertension (%) 34.9
Hyperlipidemia (%) 11.3
ABPI (mean) .5
2 Patent calf arteries (%) 83.8
Previous arterial surgery (%) 48.1
Smoking history (%)
Current 33
Ex-smoker 61.3
Never 5.7
Claudication (%) 43.4
Critical ischemia (%) 56.6
Preoperative antiplatelet therapy (%) 33
HBD, Heparin-bonded Dacron; PTFE, polytetrafluoroethylene; ABPI, ank
Table II. Life-table analysis of primary patency rate for
heparin-bonded Dacron grafts (N  106)
Year
At
risk
No. of
occlusions Died
Cumulative
patency rate SE%
1 70 29 7 .7156 8.96
2 57 36 13 .6415 9.62
3 45 44 17 .5487 10.24
4 37 47 22 .5103 10.44
5 50 32 24 .4681 10.66
Table III. Life-table analysis of primary patency rate for
polytetrafluoroethylene grafts (N  103)
Year
At
risk
No. of
occlusions Died
Cumulative
patency rate SE%
1 62 39 2 .6204 9.58
2 49 51 3 .5001 9.92
3 42 56 5 .4477 9.94
4 35 61 7 .3917 9.88
5 25 64 14 .3555 9.823-year cumulative patency rate in prosthetic grafts (65%) tothe AK popliteal artery in patients taking platelet inhibitory
therapy than that with saphenous vein (63%).14 Although
this aspect of the study was not randomized, it is generally
believed that patients with saphenous vein suitable for
grafting are at lower risk for graft failure. This parity was
reiterated byWhittemore et al,9 who reviewed several stud-
ies showing no difference in patency between vein and
PTFE for AK femoropopliteal grafts.
There is increasing evidence that prosthetic grafts, cov-
ered with platelet inhibitory drug therapy, may be im-
planted as the graft of first choice in AK femoropopliteal
bypass, enabling the saphenous vein to be conserved for
later use, if required.7,17-23 Dacron is a durable material
that, in knitted form, is easy to suture. Coated grafts
removed the need to pre-clot, improved convenience, and
may reduce the high thrombogenicity previously associated
with Dacron. At follow-up to 10 years, remarkably similar
patency rates of 32% and 31%, respectively, were achieved
with Dacron and PTFE in AK femoropopliteal bypass to
treat intermittent claudication.17
With approximately 30% of prosthetic bypasses failing
within 2 years,14 femoropopliteal reconstruction is the ideal
“test bed” for new vascular materials. Despite the range of
potential prosthetics, PTFE clearly predominates in current
femoropopliteal practice. At the time recruitment to this
study began in October 1994, no randomized clinical trials
had been published that compared Dacron with PTFE.
Our objective was amulticenter clinical trial to compare
the patency of PTFE (Atrium; W. L. Gore and Impra Ltd)
and collagen-coated HBD (InterVascular) grafts in femo-
ropopliteal bypass. The principal outcome measure was
PTFE
(N  103) P
65.39 .43
35–86
64.1 .46
35.9
26.2 .35
9.7 1.00
18.4 1.00
13.6 1.00
37.9 .076
8.7 .70
.5319 .63
77.6 .44
52.4 .47
32 .83
60.2
7.8
43.1 1.00
56.9
51.5 .01
hial pressure index.D
106)
0
3
276duration of primary patency.
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with a review of results after all grafts had been implanted
for a minimum of 2 years.13 Participating surgeons were
free to choose saphenous vein whenever this was avail-
able, but prosthetic bypass to the AK popliteal artery
could be performed in preference to saphenous vein.
Prosthetic grafts were only implanted BK when saphe-
nous vein was absent or inadequate. Full details of design
and methods are given in our previous paper,13 and are
summarized here.
METHODS
Ethical approval was obtained, and all subjects gave writ-
ten informed consent. A trial coordinator was employed to
encourage complete participation, prevent protocol viola-
tions, and independently evaluate patency using objective
criteria. Patients undergoing elective AK reconstruction and
those patients undergoing BK bypass where saphenous vein
was of poor quality or unavailable were considered with the
inclusion criteria listed in our first paper.13 Sixteen participat-
ing surgeons at 11 hospitals in northwest England submitted
352 patients for possible recruitment. Femoropopliteal bypass
was defined as the proximal anastomosis to the common,
profunda, or superficial artery above the adductor canal, and
distal anastomosis to the popliteal artery above or below or to
the tibioperoneal trunk. All eligible patients for whom distal
anastomosis was planned to be above the knee joint could be
randomized to the HBD or PTFE group. Where reconstruc-
tion was to be performed to the BK popliteal artery or tibio-
peroneal trunk, randomizationwas only appropriate when the
ipsilateral saphenous vein was absent or inadequate.
Preoperative assessment. Each patient underwent de-
tailed preoperative evaluation by the trial coordinator, includ-
ing full medical history, examination of affected limb with
Fig 1. Primary patency at life table analysis for heparin-
for years 1, 3, and 5, compared with 62%, 44%, and 35%palpation of pulses, and recording of ankle-brachial pressureindexwith hand-heldDoppler probe. Aspirin, 300mg/d,was
prescribed for all patients unless they were intolerant.
Randomization. Randomization, stratified for AK or
BK and by surgeon, was performed for eligible patients, using
a dedicated computer program. Sealed randomization enve-
lopes (1 for AK, 1 for BK) were delivered to the vascular
surgeon before surgery. The trial coordinator followed up all
patients at 3-month intervals for 1 year, and at 6-month
intervals thereafter. At each visit detailed records were taken,
documenting changes in medical history, smoking habits,
drug therapy, and current symptoms. Graft patency was inde-
pendently assessed with objective criteria.13
Sample size, trial end points, and statistical analysis.
It was estimated that a one-third difference (33%) in graft
thrombosis rate with either material would be clinically
important. To achieve an 80% power to identify this differ-
ence with conventional 5% significance, 126 patients were
required in each treatment group (withdrawal of a number
of patients resulted in a power of 72%). The statistical
methods are reported in our 2001 paper.13 The difference
in patency between the 2 graft materials was compared with
the Kaplan-Meier life table method, and analyzed statisti-
cally with the log rank test. The influence of various risk
factors on patency was examined with multivariate analysis.
The design and analysis of this trial fulfils the objectives for
clinical trials suggested by statisticians in both the United
Kingdom and the United States.24,25
RESULTS
Between October 1994 and February 1997, 352 pa-
tients were referred to the trial coordinator by 16 surgeons
from 11 centers in northwest England. Only prosthetic
grafts implanted by surgeons who adhered to the random-
ization sequence were included in the analysis; 209 patients
ed Dacron (HBD) was 71%, 54%, and 46%, respectively,
olytetrafluoroethylene (PTFE).bondwere correctly randomized, 106 HBD and 103 PTFE
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bypass grafts and 30 BK bypass grafts. One hundred forty-
three patients were excluded.13 Follow-up was for a mini-
mum of 5 years (mean, 76 months; range, 60-89 months).
Comparability of groups. Randomization achieved
comparable groups with risk factors equally distributed
between patients with HBD and PTFE grafts, with the
exception that preoperative aspirin was taken by 35 patients
in the HBD group (33%) and 53 patients in the PTFE
group (51.5%; P  .01; Table I). Preoperative symptoms
were grouped into claudication only or critical ischemia
with either rest pain or ulcers/gangrene. Overall, 90 pa-
tients (43.1%) underwent surgery to treat claudication only
(HBD, 46; PTFE, 44), and 119 patients (56.9%) were
Fig 2. A, Primary patency of above-knee grafts was 76
(HBD) at years 1, 3, and 5, compared with 66%, 49%, a
uniformly poor for below-knee bypass.operated on to treat symptoms of critical ischemia (HBD,60; PTFE, 59). The common femoral artery was used for
the proximal anastomosis in 200 procedures (95.7%). Ar-
teries used for the distal anastomosis were AK popliteal in
179 (86.1%), BK popliteal in 26 (12.4%), and tibioperoneal
trunk in 3 (1.4%). A vein patch (n  4) or Miller cuff (n 
5) was used at the distal anastomosis in 9 patients (1 AK
[HBD], 8 BK [2 HBD, 6 PTFE]).
Morbidity and mortality. Eighty complications were
reported in 77 patients (41.4%), with 47 (61%) in the HBD
group and 30 (39%) in the PTFE group (P .024).Wound
morbidity, either infection or edge necrosis, accounted for
33 complications (41%). Seventy-three patients (34.9%)
died during follow-up (HBD, 44; PTFE, 29; P  .060), 2
within 30 days (operative mortality, 1%). Grafts were
9%, and 50%, respectively, for heparin-bonded Dacron
% for polytetrafluoroethylene (PTFE). B, Results were%, 5
nd 41known to be patent up to the time of death in 37 of these
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survival at life table analysis was 82%, 72%, and 55%, respec-
tively, for years 1, 3, and 5. When all recorded risk factors
were subjected to Cox regression modeling, 3 variables
were highlighted as significant independent predictors of
mortality: diabetes (hazard ratio [HR], 2.3; 95% CI, 1.3-
4.0; P .005), symptomatic carotid disease (HR, 2.0; 95%
CI, 1.1-3.4; P .016), andmale gender (HR, 1.8; 95%CI,
1.0-3.1; P  .046).
Graft patency. After a mean of more than 6 years of
follow-up, 121 patients (58%) had primary graft occlusion,
with 53 HBD grafts failing (43.8%) compared with 68
PTFE grafts (56.2%; P .027). The highest failure rate was
in the first few months after surgery, with 68 grafts (32.5%)
becoming occluded within 12 months: HBD, 29 (42.6%);
PTFE, 39 (57.3%). Overall primary patency rate was 66%,
49%, and 40%, respectively, at 1, 3, and 5 years. Patency for
AK bypass was markedly better, at 71%, 54%. and 45%,
respectively, at 1, 3, and 5 years, compared with 38%, 19%,
and 11% for BK bypass. Occlusions were confirmed at
arteriography (n 75), duplex Doppler scanning (n 39),
and surgical exploration (n  7). Primary patency at life
table analysis at 3 years was better with HBD grafts (54%)
than with PTFE grafts (44%; P  .044), but the difference
was no longer statistically significant at 5 years: HBD, 46%;
PTFE, 35%; P  .055; Tables II and III, Fig 1). This
difference was mainly confined to AK grafts, where primary
patency for HBD was 76%, 59%, and 50%, respectively, for
years 1, 3, and 5, compared with 66%, 49%, and 41% for
PTFE (Fig 2, A; P  .142). The results for BK grafts were
uniformly poor, with primary patency for HBD at 38%,
23%, and 23%, respectively, for years 1, 3, and 5, compared
with 37%, 16%, and 0% for PTFE (Fig 2, B; P  .258).
When patients undergoing any procedure other than a
common femoral artery to AK or BK popliteal artery were
excluded, the difference between patency rates for HBD
and PTFE was statistically significant (P  .044). Patency
rates for the various PTFE grafts at 6 years were 35% for
Impra (n  85), 28% for Atrium (n  7), and 40% for
Gore-Tex (n  11), with no statistically significant differ-
ences (P  .695).
Occlusions. Of 121 primary occlusions, 30 (25%)
were treated conservatively and 11 (9%) required immedi-
ate amputation. The graft was replaced in 25 patients
(21%), who were then withdrawn from further study.
Table IV. Cumulative limb salvage with heparin-bonded
Dacron grafts (N  106)
Year
Entering
interval
No. of
amputations
Cumulative
limb salvage SE%
1 106 4 .9594 4
2 70 5 .9453 4.82
3 57 8 .8940 7.34
4 44 8 .8940 7.34
5 36 9 .8692 8.66Long-term patency was not achieved in any of the 18patients (15%) who underwent thrombolysis. Of the 12
patients (10%) who underwent surgical thrombectomy,
with or without angioplasty, long-term patency was
achieved in only 4 patients. Secondary patency at 1, 3, and
5 years was therefore similar to primary patency rates of
73%, 55%, and 47%, respectively, for HBD, compared with
63%, 48%, and 36% for PTFE (P  .052). In 3 patients
stenosis of an anastomosis was treated with angioplasty,
successfully maintaining graft patency.
Influence of risk factors. The influence of arterial
disease risk factors on patency was studied with Cox regres-
sionmodeling. These included graft material, indication for
surgery, previous arterial surgery, smoking history, symp-
tomatic carotid disease, antiplatelet therapy, gender, diabe-
tes, hypertension, hyperlipidemia, myocardial infarction or
angina, and cardiac failure. The type of graft material used
(HBD, PTFE) was a significant predictor of occlusion (HR,
1.52; 95% CI, 1.06-2.19; P  .024). Unexpectedly, grafts
were less likely to become occluded in patients with a
history of cardiac failure before surgery (HR, 0.44; 95% CI,
0.20-0.94; P  .034). However, these 20 patients had a
worse survival rate, with a median time to death of 33
months compared with 78 months in patients with no such
history (P .140). Diabetes (HR, 1.6; 95% CI, 0.96-2.60;
P  .073) and current smoking (HR, 1.3; 95% CI, 0.93-
1.9; P  .119) showed a nonsignificant trend toward
predicting occlusion. Smoking history was not supported
by objective analysis for markers of smoking.
Amputation. Major BK or AK limb amputation was
performed in 29 patients (14%), with only 9 (8.5%) follow-
ing HBD bypass and 20 (19.4%) following PTFE bypass.
Eleven of these amputations were performed as primary
procedures after graft occlusion. Overall cumulative limb
salvage at 5 years was 86% for HBD and 74% for PTFE
(Tables IV and V, Fig 3; P .025). The risk for amputation
is usually low in patients with intermittent claudication
treated conservatively. However, of the 90 patients who
underwent bypass to treat claudication, 10 (11%) subse-
quently required amputation despite attempts to reestab-
lish patency after graft thrombosis. Of these, 2 (4.3%) of 46
patients withHBD and 8 (18.2%) of 44 patients with PTFE
grafts implanted to treat claudication required amputation
(P  .080).
DISCUSSION
In this randomized multicenter study, better patency
Table V. Cumulative limb salvage with
polytetrafluoroethylene grafts (N  103)
Year
Entering
interval
No. of
amputations
Cumulative
limb salvage SE%
1 103 14 .8417 7.82
2 63 17 .7996 8.82
3 50 17 .7996 8.82
4 45 19 .7644 9.72
5 36 20 .7426 10.38rates were achieved with HBD compared with PTFE in
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longer statistically significant by 5 years. The results for
PTFE were comparable with those previously reported in
the UK randomized study that compared human umbilical
vein and PTFE where primary patency for PTFE (n 104)
was 61% and 48%, respectively, at 1 and 3 years.14 The
results for PTFE patency were also remarkably similar to
those published in a range of studies where more than 50
PTFE grafts were followed up for a minimum of 12months
(Table VI). Our results also confirm that in prosthetic
femoropopliteal bypass the graft failure rate is highest in the
early months after surgery.14 For prosthetic grafts this
failure rate is 53 per 1000 patient-months in the first 3
months, and decreases to 21 per 1000 patient-months at 6
to 12 months and around 10 per 1000 patient-months in
subsequent years.14
Publishing the results of studies of femoropopliteal
bypass is reasonable, providing all grafts have been followed
up for at least 1 year. In our study every graft was followed
up for at least 5 years (mean, 76 months). Barring the
patients who died or were lost to follow-up, censored in the
life table analysis, our patency results reflect actual patency
in grafts followed up for a minimum of 5 years, a mean of
more than 6 years, and a maximum of 8 years. This is in
contrast with many previous studies in which 3-year or
5-year follow-up refers to the maximum follow-up interval,
with the mean follow-up for 3-year studies less than 20
months and for 5-year studies less than 2 years.4,6,7 The
high amputation rate after PTFE bypass in our study in-
cluded 8 patients in whom the original indication for
surgery was claudication only. This is perhaps the most
important result, because conservative treatment of inter-
mittent claudication is associated with low risk for subse-
quent amputation.26 Amputation results in the current
Fig 3. Cumulative limb salvage at 5 years was 86% for h
ethylene (PTFE).study were no worse than those previously published forPTFE (Table VII). TheMedical Research Council study, in
particular, perhaps the largest study of this type, reported
amputation in 23 patients (22%) with PTFE grafts.14 The
amputation rates reported in Table VII demonstrate a
dramatic variability that is difficult to explain. The rates
appear to be lower in those studies in which the follow-up
interval was short, with 3-year or 5-year follow up based on
life table predictions.
Controversy still exists concerning the role and choices
of prosthetic grafts in femoropopliteal surgery; the debate
as to whether one is superior to another remains unre-
solved. Retrospective studies include a review of 200 AK
procedures in which there was no significant difference
between PTFE and Dacron.17 This review quoted patency
rates at 5 and 10 years when mean follow-up was less than
3 years. It contrasts with a similar retrospective review at
about the same time, in which Pevec et al8 reported signif-
icantly better patency for knitted Dacron grafts than for
PTFE grafts, with a 5-year limb salvage rate (calculated
Table VI. Primary patency by life table
Author PTFE (n) Interval (y) Cumulative %
Prendiville et al27 114 3 47.5
McCollum et al14 103 3 48
Pevec et al8 85 3 34
John et al28 113 2 58
Abbot et al7 119 3 57.6
Jackson et al29 81 3 36
Green et al4 122 3 61
Post et al3 91 3 61
Curi et al30 141 2 50
Robinson et al31 68 2 47
Present study 103 3 44
in-bonded Dacron (HBD) and 74% for polytetrafluoro-eparwith life table analysis) of only 61% for PTFE and 79% for
JOURNAL OF VASCULAR SURGERY
November 2004930 Devine et alknitted Dacron. More reliance can clearly be placed on
randomized clinical trials with the study by Abbott et
al,7published first in 1997 with mean follow-up less than a
year and subsequently in 2000 with mean follow-up ap-
proaching 2 years, which showed equivalent patency rates
for Dacron and PTFE at life table analysis.4 The random-
ized prospective multicenter study performed in Germany
by Post et al3 included 103 Dacron grafts and 91 PTFE
grafts, with mean follow-up of 36 months. The analysis
included 53 patients with BK bypass with 3-year patency
rate for Dacron at 64% and for PTFE at 61%. Limb salvage
rates were also similar. Of interest, AK patency tended to be
better with Dacron, with BK patency tended to be better
with PTFE, although in very small numbers. In a previous
study, in which approximately 70% of bypasses had been
AK, 3-year patency rate for PTFE was 52%, more closely
similar to that generally quoted, but again with a mean
follow-up of only 19 months.6 The HBD patency rate in
our study contrasts with the equivalent patency rates for
Dacron and PTFE reported in other similar trials.4,6,7 It is
possible that the difference in patency achieved between
HBD and PTFE in our studymay be due to the influence of
heparin bonding. The PTFE patency rates that we report
are no worse than those reported in similar studies.
Our results demonstrate that when the surgeon adopts
a strategy of using prosthetic grafts for AK bypass or where
the vein is absent or inadequate for BK femoropopliteal
bypass, HBD achieves statistically significant patency rates
compared with PTFE up to 3 years, although this differ-
ence is no longer statistically significant at 5 years.
Inasmuch as our grafts were predominantly 6 mm,
there was no opportunity to analyze the influence of graft
diameter on patency. Furthermore, when the operating
surgeon had a choice, larger diameter grafts would be more
likely to be implanted in larger patients with bigger arteries.
This bias may explain the improved patency with larger
grafts reported by the AK femoropopliteal study group led
by Abbott et al.7
The high amputation rate after PTFE bypass, particu-
larly in patients with claudication only, is comparable to
that in a previous major study,14 and suggests that this
material may have unique features that increase the risk for
subsequent amputation. We can only speculate that distal
embolizationmay occur from PTFE grafts before final graft
thrombosis.
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